文献速递神经肌肉病

杜氏肌营养不良症新生儿筛查:实施早期诊断范式的当代考量

Newborn Screening for Duchenne Muscular Dystrophy: Contemporary Considerations for Implementation of an Early Diagnostic Paradigm.
PubMed 文献 · Neurology · 2026-11-11

综述概述杜氏肌营养不良症(DMD)新生儿筛查的当代方法,包括采用肌酸激酶肌肉亚型(CK-MM)检测及基因组测序的多步骤算法。7项试点研究显示,重复干血斑检测和分子遗传分析可提高阳性预测值,但干血斑重采的脱落率为17.1%(108/632)。理想筛查算法、成本效益及早期启动疾病修正治疗的最佳时机尚待研究。

要点

  • 2020年美国FDA批准高通量检测后,DMD新生儿筛查多采用CK-MM检测,7项试点研究采用不同算法。
  • 对初始CK-MM升高者重复干血斑检测可提高阳性预测值,加做DMD基因组分析后阳性预测值达100%。
  • 多步骤筛查中干血斑重采脱落率为17.1%(108/632),筛查算法选择决定所检出疾病的范围。

核心结论

  • 卫生系统准备、跨国合作及多学科团队协调机制对通过新生儿筛查实现DMD早期诊断至关重要。
  • 需利用大型系统数据集评估筛查算法、评估成本效益、探索使用经验证结局测量工具更早启动疾病修正治疗,并建立循证照护模式以支持全球实施。

研究设计与样本

  • 综述,总结当前DMD新生儿筛查方法及基因组测序在筛查算法中的作用,并讨论以家庭为中心的照护模式。

主要发现

  • 自2020年美国FDA批准高通量检测后,当代DMD新生儿筛查项目采用肌酸激酶肌肉亚型(CK-MM)检测。
  • 来自中国、台湾和美国的7项试点研究采用不同筛查算法报告了结果。
  • 对初始CK-MM升高者纳入重复干血斑检测,较单样本筛查提高了阳性预测值。
  • 对持续CK-MM升高婴儿纳入DMD分子基因组分析,阳性预测值进一步提高至100%;但多步骤方法中干血斑重采的脱落率为17.1%(108/632)。
  • 筛查算法选择决定所检出疾病的范围;疾病修正治疗的最佳启动时机尚不确定,是未来研究的关键优先事项。

关键数值与推荐

  • 对初始CK-MM升高者重复干血斑检测可提高阳性预测值。
  • 对持续CK-MM升高婴儿加做DMD分子基因组分析后阳性预测值达100%。
  • 多步骤筛查中确认检测前干血斑重采脱落率为17.1%(108/632)。

临床怎么用

  • DMD早期生命阶段的推荐照护模式包括遗传学、社会心理支持、对认知行为情绪困难的主动监测与个体化支持、获取教育资源和支持网络以及临床试验准备。

局限性

  • 疾病修正治疗的最佳启动时机尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF REVIEW: The need for earlier diagnosis of Duchenne muscular dystrophy (DMD) is increasingly recognized, prompting consideration of its routine inclusion in newborn screening (NBS) programs and its addition to the Recommended Universal Screening Panel in the United States in December 2025. This review provides an overview of current approaches to DMD NBS, including the role of genomic sequencing for DMD variants in NBS algorithms. In an evolving model of care, the challenges and potential factors that may strengthen the practice of family-centered care are considered. RECENT FINDINGS: Contemporary DMD NBS programs have adopted measurement of the muscle isoform of creatine kinase (CK-MM), after US Food and Drug Administration approval of high-throughput assays in 2020. Since then, 7 pilot studies from China, Taiwan, and the United States have reported outcomes using varied screening algorithms. Those incorporating repeat dried blood spot (DBS) testing after an initially elevated CK-MM level increased the positive predictive value compared with single-sample screening. Incorporating molecular genomic analysis of DMD in infants with persistently elevated CK-MM levels further increased the positive predictive value to 100%; however, this multistep approach also highlighted the practical challenges of DBS recollection, with a 17.1% (108/632) attrition rate before confirmatory testing. The choice of screening algorithm also determined the scope of conditions identified. The optimal timing for initiation of disease-modifying therapies is uncertain, and this represents a key priority for future research. The recommended model of care for DMD in early life incorporates genetics; psychosocial support; proactive monitoring and individualized support for cognitive, behavioral, and emotional difficulties; access to educational resources and support networks; and clinical trial readiness. SUMMARY: Health system preparedness, collaboration across countries, and coordination mechanisms within a multidisciplinary team are important for building effective health care in the context of early diagnosis of DMD through NBS. There is an ongoing need to evaluate screening algorithms using large systematic data sets, assess their cost-effectiveness, explore the potential for earlier initiation of disease-modifying treatments with validated outcome measurement tools, and establish a comprehensive evidence-based model of care to support global implementation of DMD within NBS programs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Yau UTE, Lorentzos M, Kariyawasam D, et al. Newborn Screening for Duchenne Muscular Dystrophy: Contemporary Considerations for Implementation of an Early Diagnostic Paradigm. Neurology. 2026. PMID: 43013792. doi:10.1212/WNL.0000000000218717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。